Loading
A phase 2 trial in lung cancer, run by Shenzhen Celconta Life Science Co., Ltd., not yet recruiting.
PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC is a phase 2, interventional study registered as NCT07043907 by Shenzhen Celconta Life Science Co., Ltd., with a registry enrolment figure of 115 participants, started 2025-07-08 and due to reach its primary completion in 2028-07-08. Interventions recorded: PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy. Conditions listed: Stage IIIA Non-small Cell Lung Cancer. Primary outcome: Incidence and severity of adverse events (AEs); Disease Free Surviva Percentage（DFS%）. Lung eligibility wording from the registry: "Patients with histologically confirmed stage IIIA NSCLC (T4N0M0, T3-4N1M0, T1a-2bN2M0) who underwent R0 resection and received postoperative adjuvant chemotherapy (Exclusion of EGFR sensitizing mutations and ALK fusion); and who received the first dose of PANK-003 cell injection combined with postop". No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.